Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
31.67
+0.54 (1.73%)
Dec 20, 2024, 4:00 PM EST - Market closed
Guardant Health Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Guardant Health stock have an average target of 39.93, with a low estimate of 32 and a high estimate of 50. The average target predicts an increase of 26.08% from the current stock price of 31.67.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 7, 2024.
Analyst Ratings
The average analyst rating for GH stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 10 | 10 | 10 | 10 | 10 |
| Buy | 6 | 6 | 6 | 6 | 6 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 17 | 17 | 17 | 17 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $48 → $50 | Buy | Maintains | $48 → $50 | +57.88% | Nov 7, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $32 → $36 | Strong Buy | Maintains | $32 → $36 | +13.67% | Nov 7, 2024 |
| Bernstein | Bernstein | Buy Maintains $40 → $35 | Buy | Maintains | $40 → $35 | +10.51% | Oct 30, 2024 |
| UBS | UBS | Strong Buy Maintains $32 → $40 | Strong Buy | Maintains | $32 → $40 | +26.30% | Aug 21, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $30 → $34 | Buy | Maintains | $30 → $34 | +7.36% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
745.70M
from 563.95M
Increased by 32.23%
Revenue Next Year
871.73M
from 745.70M
Increased by 16.90%
EPS This Year
-3.53
from -4.28
EPS Next Year
-3.02
from -3.53
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 763.6M | 968.8M | 1.2B | |||
| Avg | 745.7M | 871.7M | 1.1B | |||
| Low | 707.3M | 791.5M | 874.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 35.4% | 29.9% | 33.3% | |||
| Avg | 32.2% | 16.9% | 20.6% | |||
| Low | 25.4% | 6.1% | 0.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.10 | -1.91 | -0.92 | ||
| Avg | -3.53 | -3.02 | -2.41 | ||
| Low | -3.66 | -4.00 | -4.40 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.